Hosted on MSN27d
Novo's Rybelsus results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...
Hosted on MSN7mon
Lexaria gets ethics board okay for oral GLP-1 study
The study will evaluate a 7mg dose of Rybelsus, a pill formulation of the drug semaglutide, processed with DehydraTECH both as a swallowable capsule and as an oral dissolvable tablet. The study is ...
Yahoo Finance27d
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...
Yahoo Finance29d
Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics
The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney ...
Seeking Alpha27d
Novo's Rybelsus CV results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...